Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jaros

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Sleep Medicine|May 21, 2016
Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndromeDaniel O Lee, Mark J Buchfuhrer, Diego Garcia-Borreguero, et al.
European Heart Journal|November 4, 2022
Effect of inclisiran on lipids in primary prevention: the ORION-11 trialKausik K Ray, David Kallend, Lawrence A Leiter, et al.
Journal of Hepatology|December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitisMary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Nature Biomedical Engineering|September 30, 2024
A fast all-optical 3D photoacoustic scanner for clinical vascular imagingN T Huynh, E Zhang, O Francies, et al.
The New England Journal of Medicine|March 21, 2020
Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J Raal, David Kallend, Kausik K Ray, et al.
European Heart Journal|November 4, 2022
Inclisiran and cardiovascular events: a patient-level analysis of phase III trialsKausik K Ray, Frederick J Raal, David G Kallend, et al.
Hepatology (Baltimore, Md.)|February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2013
Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometryTheodoros A Koutroukides, Julian A J Jaros, Bob Amess, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Sleep Medicine|May 21, 2016
Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndromeDaniel O Lee, Mark J Buchfuhrer, Diego Garcia-Borreguero, et al.
European Heart Journal|November 4, 2022
Effect of inclisiran on lipids in primary prevention: the ORION-11 trialKausik K Ray, David Kallend, Lawrence A Leiter, et al.
Journal of Hepatology|December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitisMary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Nature Biomedical Engineering|September 30, 2024
A fast all-optical 3D photoacoustic scanner for clinical vascular imagingN T Huynh, E Zhang, O Francies, et al.
The New England Journal of Medicine|March 21, 2020
Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J Raal, David Kallend, Kausik K Ray, et al.
European Heart Journal|November 4, 2022
Inclisiran and cardiovascular events: a patient-level analysis of phase III trialsKausik K Ray, Frederick J Raal, David G Kallend, et al.
Hepatology (Baltimore, Md.)|February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2013
Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometryTheodoros A Koutroukides, Julian A J Jaros, Bob Amess, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Pageof 5